Efficacy of duloxetine, a potent and balanced serotonin-norepinephrine reuptake inhibitor in persistent pain models in rats.
about
Serotonin-norepinephrine reuptake inhibitors for pain control: premise and promiseDoes central sensitization help explain idiopathic overactive bladder?Tramadol and propentofylline coadministration exerted synergistic effects on rat spinal nerve ligation-induced neuropathic painDuloxetine Inhibits Microglial P2X4 Receptor Function and Alleviates Neuropathic Pain after Peripheral Nerve InjuryAn integrated perspective on diabetic, alcoholic, and drug-induced neuropathy, etiology, and treatment in the US.Treatment of diabetic sensory polyneuropathy.Safety and tolerability of duloxetine in the acute management of diabetic peripheral neuropathic pain: analysis of pooled data from three placebo-controlled clinical trials.Superiority of duloxetine to placebo in improving diabetic neuropathic pain: Results of a randomized controlled trial in JapanDiscovery of a potent, dual serotonin and norepinephrine reuptake inhibitorCentral sensitization: implications for the diagnosis and treatment of pain.Treatment-emergent sexual dysfunction with SSRIs and duloxetine: effectiveness and functional outcomes over a 6-month observational period.Understanding central mechanisms of acupuncture analgesia using dynamic quantitative sensory testing: a review.A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain.Maintaining efficacy in the treatment of diabetic peripheral neuropathic pain: role of duloxetineEvidence for a differential opioidergic involvement in the analgesic effect of antidepressants: prediction for efficacy in animal models of neuropathic pain?Metabolomic identification of biochemical changes induced by fluoxetine and imipramine in a chronic mild stress mouse model of depression.A spinal mechanism of action for duloxetine in a rat model of painful diabetic neuropathyMechanical Antiallodynic Effect of Intrathecal Nefopam in a Rat Neuropathic Pain Model.Efficacy of Duloxetine in Patients with Chronic Pain ConditionsEfficacy of duloxetine add on in treatment of inflammatory bowel disease patients: A double-blind controlled study.Effects of milnacipran, a 5-HT and noradrenaline reuptake inhibitor, on C-fibre-evoked field potentials in spinal long-term potentiation and neuropathic painDuloxetine in diabetic neuropathy.A Review of Adjunctive CNS Medications Used for the Treatment of Post-Surgical Pain.Duloxetine: a new selective and dual-acting antidepressant.Perspectives on next steps in classification of oro-facial pain - Part 3: biomarkers of chronic oro-facial pain - from research to clinic.Review of duloxetine in the management of diabetic peripheral neuropathic pain.Altered pain modulation in patients with persistent postendodontic painPharmacological comparison of a nonhuman primate and a rat model of oxaliplatin-induced neuropathic cold hypersensitivity.Duloxetine in OsteoArthritis (DOA) study: study protocol of a pragmatic open-label randomised controlled trial assessing the effect of preoperative pain treatment on postoperative outcome after total hip or knee arthroplasty.Brain derived nerve growth factor induces spinal noradrenergic fiber sprouting and enhances clonidine analgesia following nerve injury in ratsTreatment of fibromyalgia and its symptoms.Emerging drugs for osteoarthritis.Janus molecule I: dichotomous effects of COMT in neuropathic vs nociceptive pain modalities.Multiplicative interactions to enhance gabapentin to treat neuropathic pain.Antidepressant agents for the treatment of chronic pain and depression.Arthralgias, bodily aches and pains and somatic complaints in midlife women: etiology, pathophysiology and differential diagnosis.Effects of monoamine reuptake inhibitors in assays of acute pain-stimulated and pain-depressed behavior in ratsIdentification of differentially expressed genes by gabapentin in cultured dorsal root ganglion in a rat neuropathic pain modelEvaluation of the analgesic effects of ammoxetine, a novel potent serotonin and norepinephrine reuptake inhibitor.Personalized pain medicine: the clinical value of psychophysical assessment of pain modulation profile.
P2860
Q24657417-3C0EBFE2-C8A9-4264-B600-727BD0D63016Q26744440-2A18C063-F87E-466C-8244-A6F82C9AC842Q28535929-CB4B565F-0CC6-4618-9FA2-D6BE733B79BFQ28552863-85361370-3512-42BE-92B5-A3E920E644CCQ30236003-A2D05969-F914-4945-93BB-048C1FBB740AQ33393882-3FEA5954-BA4F-4B5D-88BB-CE2A3FB4B7F6Q33577285-84EC7CE3-8221-4D2A-A0B4-435ABFA21ECDQ33588319-CA3E0D17-1C9F-4DC0-BDEF-525C28CF7710Q33635965-2B1960AE-A0B1-45C0-BB89-1AEFC846D3F6Q34144741-C5E248AB-D3D0-4609-A327-3DECFD763CF5Q34236311-E3C50004-C261-427B-9BFF-92006BC672DCQ34350575-3F32F45E-190F-4FDC-BD13-3466A6B286F7Q34464747-0630AB7D-F4C2-4A22-A743-1B275B7ECB2CQ34620539-DF789BFF-5090-4E6C-B248-369F7A36A4BEQ35036180-D8958D30-156D-41B5-9E32-A4565F550CA8Q35157192-E7444FAA-AB92-4696-B3EF-5ADB37E94409Q35210048-1D73FCB4-7539-4764-AA08-34C55D423080Q35905164-03F0CE8F-E979-4F4F-89C6-F929738A3C47Q36141335-772B357B-36C7-4472-91A4-5EE6DF493881Q36210044-058F1419-86D0-4415-86B4-02479D1CFC86Q36253994-CBC7BDB3-EEE7-4586-9BC4-F81523AAC6FEQ36376417-22DB6AD1-8BF7-4CDA-B73C-79739846A4C8Q36391635-16993F16-0FAB-4E18-BC97-DDE2357C5332Q36407366-009986E2-8B73-40AE-8B06-125A11F0BEF4Q36469849-0010D8B6-1A31-4572-B528-1E784204BF6DQ36596907-5DF506DD-9DD9-4A3F-8F06-7067E23F8E8BQ36628282-37A7103D-C1FD-425F-8213-30BA53662FC1Q36648880-A426CF6F-14F9-45C1-827A-8F38928B743EQ36670614-6238535D-E011-4ECE-BA05-9212EE6F7DE9Q36793984-6F8905F7-B488-4088-8EDC-CB400E36CD2CQ36904884-C0515666-DE7F-4981-A4C2-F979F7C49CEAQ36931658-CD049845-5F0F-401A-8A47-A39FAC1E53BCQ36972453-450B3C9C-1E74-448C-AD40-75872E2AEF61Q36972856-8F6990EA-EF8D-48E9-A8FE-FAACD233CAFFQ36982694-BD8355C1-7053-4590-8D63-801149BF9A36Q37014601-548FB51F-EB93-42C7-868E-3BBC09526EF9Q37095221-9F5692E0-8030-4D28-B9C1-FEB9D018A742Q37145569-12B6416F-66A0-4CC0-AF87-80AC66E850D9Q37254569-104F5D12-4619-423B-8D82-8949B9B4C182Q37287551-A46AC7E5-C876-4C95-BAAB-F784D8ABDEA2
P2860
Efficacy of duloxetine, a potent and balanced serotonin-norepinephrine reuptake inhibitor in persistent pain models in rats.
description
2004 nî lūn-bûn
@nan
2004 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Efficacy of duloxetine, a pote ...... ersistent pain models in rats.
@ast
Efficacy of duloxetine, a pote ...... ersistent pain models in rats.
@en
Efficacy of duloxetine, a pote ...... ersistent pain models in rats.
@nl
type
label
Efficacy of duloxetine, a pote ...... ersistent pain models in rats.
@ast
Efficacy of duloxetine, a pote ...... ersistent pain models in rats.
@en
Efficacy of duloxetine, a pote ...... ersistent pain models in rats.
@nl
prefLabel
Efficacy of duloxetine, a pote ...... ersistent pain models in rats.
@ast
Efficacy of duloxetine, a pote ...... ersistent pain models in rats.
@en
Efficacy of duloxetine, a pote ...... ersistent pain models in rats.
@nl
P2093
P356
P1476
Efficacy of duloxetine, a pote ...... ersistent pain models in rats.
@en
P2093
Amy A Webster
Jimmy Yu Xu
Rosa Maria A Simmons
Smriti Iyengar
Susan K Hemrick-Luecke
P304
P356
10.1124/JPET.104.070656
P407
P577
2004-07-13T00:00:00Z